JP Patent

JP2019503989A — 軟膏剤

Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2019-02-14 · 7y expired

What this patent protects

ＰＤＥ４に対する特異的な阻害作用を有する下記式（１１）で表されるオキサゾール化合物を安定に含有し、且つ皮膚内へ効率よく吸収され得る軟膏剤が提供される。【選択図】なし

USPTO Abstract

ＰＤＥ４に対する特異的な阻害作用を有する下記式（１１）で表されるオキサゾール化合物を安定に含有し、且つ皮膚内へ効率よく吸収され得る軟膏剤が提供される。【選択図】なし

Drugs covered by this patent

Moizerto (DIFAMILAST) · OTSUKA PHARMACEUTICAL Co., Ltd

Patent Metadata

Patent number: JP2019503989A
Jurisdiction: JP
Classification: —
Expires: 2019-02-14
Drug substance claim: No
Drug product claim: No
Assignee: Otsuka Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.